Introduction
Fibromyalgia (FM), chronic low back pain (CLBP) and ankylosing spondylitis (AS) are three chronic musculoskeletal disorders with differences in epidemiology, etiopathogenesis, and clinical signs and symptoms. FM and CLBP are considered to be a somatoform pain disorder following the DSM IV classification [1] while AS is considered to belong be a autoimmune inflammatory diseases. The estimated prevalence of the three conditions in adult Western populations varies between 4 and 14% for FM [2] , between 20 and 50% for CLBP [2] and between 0.1 and 1.1% for AS [3] . In FM and CLBP there are typically no inflammatory changes detectable in laboratory assessments and there are no structural changes of the joints or spine. On the other hand, about 50% of patients with AS have an increased sedimentation rate or CRP [4] and by definition all patients have radiographic sacroiliitis.
Despite the absence of inflammatory and structural abnormalities, it is known that patients with FM and CLBP express important influence of the disease on pain, physical function, and general well being [5] .
Although the costs per patient have been reported in three studies for FM [6] [7] [8] , one study for CLBP [9] and two studies for AS [10] [11] [12] , no study yet performed a comparison of costs between the diseases. Indirect comparisons of cost-of-illness (COI) studies cannot be done reliably, mainly because of differences in the method to collect resource use and the method to value resource use in monetary terms. Notwithstanding, comparisons can identify diseases that incur high costs, their cost-drivers and the variables associated with costs. This can help setting priorities for future studies as to the effectiveness of health interventions and healthcare services. In this study we were interested if patients with an unexplained pain syndrome (such as FM and CLBP) have a different pattern of healthcare consumption and productivity loss compared with a patients having a specific inflammatory rheumatic disorder such as in AS, independent of the differences in perceived well-being.
Methods

Patients
Patients included in this comparison had participated in three different piggy-back cost-utility studies, which have been published previously [13] [14] [15] . The patients with FM and CLBP participated between 1993 and 1995 in a randomised clinical trial (RCT) comparing the costeffectiveness of a six (FM) or 8 weeks (CLBP) cognitive-behavioural rehabilitation program with a discussion control and a waiting list control group. Patients with FM could be referred by the rheumatologist or the rehabilitation physician if they were older than 18 years, fulfilled ACR classification criteria for fibromyalgia, encountered hindrances in fulfilling desired activities and were prepared to participate in the 6 weeks' interventionPatients with chronic low back pain participated between 1993 and 1995 in a randomised clinical trial examining the cost-effectiveness of an 8 weeks' cognitive-exercise rehabilitation program compared with an attention control group and a waiting list control group. Patients could be referred for the study by the general practitioner, the rheumatologist or the rehabilitation physician if they were older than 18 years, had low back pain since more than 6 months without evidence of a specific spinal disease and were prepared to participate in the study. Follow-up for both studies was 52 weeks [13] . Patients with AS participated between in 1999 in a randomised controlled trial comparing the cost-utility of a three weeks spa-exercise treatments in Austria or a three weeks spa-exercise treatment in the country of residence (The Netherlands) with usual care waiting list control group. Patients were recruited through the AS patients society.
They could be included if they were older than 18 years, fulfilled the modified New York criteria for AS, had pain, stiffness and functional limitations in the three months before the start of the study and were available to participate. The study follow-up was 40 weeks [15] .
Data sources
All patients completed at the start of the study a questionnaire on socio-demographic characteristics. Clinical evaluations were study-specific and took place at pre-set time-points during the course of the trial. During the entire follow-up, patients in all three studies completed cost-diaries on disease specific resource use. Demographic variables Each study assessed gender, age, cohabitation status, highest educational level, engagement in paid work and hours of paid work per week and finally presence of work disability and, if applicable the level (full or partial) of work disability. For the statistical analyses the educational level was dichotomised into low and high educational level distinguishing patients who had achieved a university or higher non-university degree.
Clinical outcome variables
Only two clinical variables were assessed similarly in each of the three studies. In all studies, patients had to report disease duration since onset of sympotoms. To assess global well being, a rating scale (0-100; higher values indicating better well being) visualized as a thermometer was included in the three studies; as a separate instrument in the FM and CLBP study [16, 17] and as part of the EuroQol in the AS study [18] .
Resource utilization.
We aimed to evaluate the societal perspective of resource utilisation and therefore the direct healthcare and non-healthcare resource utilisation and productivity losses were considered.
In the three studies the cost diaries developed and partially validated by Goossens were used [19] . Patients were instructed to report only the disease related resource utilisation and not to report utilisation related to the study protocol.. Since in the AS study the resources were recorded for a period of 40 weeks, results were extrapolated to 52 weeks. In case of missing cost-diaries, mean values over the available time were extrapolated to one year for all three conditions.
Sources of costs estimate.
All resources recorded in the diaries were valued for this analysis by cost-estimates of the year 2002.True cost-estimates are available in the Dutch Guideline for Pharmacoeconomic Studies [20] . The costs per unit were adjusted to 2002 costs by applying the healthcare consumer price indices (CPI) to all medical resources and by applying the CPIs based on the gross national product (GNP) for the unit costs of formal and informal care and for the loss of paid productivity [21] . Costs for alternative medicine, informal care, over the counter drugs and aids and appliances were reported directly (including patient contribution) by the patients in the diaries and were adjusted for differential timing using the appropriated CPI [22] . The costs of prescribed and over-the-counter drugs were calculated using the wholesale prices.
For prescription drugs, an additional pharmacist's fee of € 4.64 per prescribed item (with a maximal prescription period of three months) was added to calculate the total costs of prescription drugs since this was practice in the Netherlands. When valuing the costs of personal inactivity reported by the patients, the hours of formal and informal help received were subtracted from the hours of inactivity reported by the patient in order to avoid double counting. The sources and values of cost-estimates for each resource can be seen in Appendix I.
The productivity costs because of loss of paid labour were calculated by applying the friction costs method, which limits the period of production loss to the time the work of the diseased person is not replaced (the friction period) [23] . In 2002, the length of the friction period was set at 22 weeks (110 working days). Paid production was valued by the average national gross wage per hour differentiated for gender and five different age categories [22] . Since patients reported the number of (half) working days absent, it was considered that one working day comprises on average eight working hours.
Statistical analysis
Labour force participation and work disability rates were adjusted to the Dutch general population by indirect standardisation for gender and 5 age categories [22] .Univariate differences in costs among groups were assessed by the 95 percentile bootstrapped confidence intervals of the difference after 1,000 replications.
Several multivariate regression analyses were computed with direct (healthcara and nonhealthcare), indirect and total costs as outcome. In all analyses, diagnostic group and assigned intervention were forced into a first block and all other demographic (agen, gender, educational level and marital status) and disease related (disease duration and generall well being) variables into a second block applying a backward elimination procedure. Interactions between diagnostic group and each of the other variables were examined. Since data on costs were skewed we computed linear regression analyses on the log-transformed costs test the (geometric) mean costs, Cox proportional hazard analyses with costs as outcome test the association of variables with median costs and logistic regressions (distinguishing the 25% of patients with the highest costs) test the outliers. Since all regression models provided similar results, it was decided to show the data of The Cox proportional regressions becasue they allow to visualise differences between groups in figures, and the regression coefficients are easy interpretable. . Separate Cox proportional regression analyses were to test the influence of diagnosis (first block) adjusted for age, gender, disease duration and educational level (second block) on general well being Again, interactions between the diagnostic group and each of the other independent variables were tested.
Sensitivity analyses
Since only patients with CLBP specifically mentioned such visits as a separate resource within the open-ended answering category "visits to other healthcare providers", it could not be excluded the patients with FM and AS did not consider these visits. Therefore, in the sensitivity analyses the direct medical, total direct and direct plus productivity costs were recalculated after excluding the costs due to psychotherapy reported by patients with CLBP.
In a second sensitivity analysis we considered the friction period to be 14 weeks (70 working days) instead of 22 weeks (110 working days). In 2002 the employment in the Netherlands was more favourable than in the years of each of the original studies resulting in a longer friction period.
Results
Patients
Altogether, 131 patients with FM, 135 patients with chronic CLBP and 120 patients with AS had been randomised in the initial cost-utility studies. Since the waiting list control group of patients with FM (n=43) did not take part in the economic analyses because they continued after the 6 weeks assessment to usual care, only 70 patients with FM, but 110 with CLBP and 111 with AS could be included in this study. Patients included in the cost-analysis were not significantly different in socio-demographic and disease characteristics with those not included, except for patients with CLBP being significantly older compared with the nonincluded (41 versus 37; p=0.01). Table1 compares socio-demographic and clinical characteristics of the included patients. Patients with AS had longer disease duration, a higher educational level and a lower work disability rate. In case of work disability they were more often partially work disabled.
General well-being and determinants
General well-being was remarkably lower in patients with FM and chronic CLBP compared to AS patients (Table 1) . In univariate analyses patients with FM had a 3.0 (95%CI: 2.1-4.1) and patients with CLBP a 3.9 (95%CI: 2.9-5.3) increased risk for lower general well being compared with AS patients. No other socio-demographic or disease related variables contributed to differences in well being among the diseases.
Costs
The average annual resource utilisation and costs per patient for each of the three conditions are provided in Table 2 and Table 3 . Total direct costs were higher in patients with FM or CLBP compared with AS because of higher direct non-medical costs. Within the direct medical costs, cost drivers were visits to healthcare providers for patients with FM (29% of the costs) and CLBP (29% of the costs) compared with visits to physiotherapy (43% of the costs) for patients with AS. Notwithstanding the lower proportion of patients with FM and CLBP who had a paid job and their somewhat lower average income (FM: €16.3/hour, CLBP: €17.0/hour and AS: €19.0/hour), the friction costs were higher. In those with a paid job 63%, 47% and 39% of patients with FM, CLBP and AS respectively reported an episode of sick leave and mean sick leave was 34, 79 and 12 days per working patient year for FM, CLBP ad AS.
Determinants of costs
Diagnostic group was the most important variable associated with direct non-medical, productivity and total costs. The treatment-assignment did not explain differences in costs for any of the cost-categories but there was an interaction between intervention and CLBP (p=0.04) for the direct non-medical costs. This can be explained by small increase in the need for unpaid help among patients with CLBP in the intervention group, a phenomenon already described in the original publication [13] . Female patients had more direct nonmedical costs but male patients had more productivity costs. There were no interactions between the diagnostic group and any of the other determinants. Figure 1 illustrates differences in costs between the diagnostic groups. Only 7.5% of patients with AS incurred more than € 10,000 total annual costs compared with more than 30% of patients with FM and 37% of patients with CLBP. In the linear regression on the log-transformed total costs, lower general well being had a slightly higher association with the total costs (B: -0.03 [95%CI: -0.001 to -0.02]; p:0.04). Within each of the diseases separately, no specific variables were associated with higher total costs in FM and CLBP while in AS lower educational level (2.9 [95% CI: 1.4-6.3]) was associated with higher total costs.
Sensitivity analyses
Excluding the costs for psychotherapists from the direct medical costs of patients with CLBP the mean annual costs per patient decreased slightly from €1,104 to € 984 and total direct cost from €5,594 to € 5,470. Reducing the friction period to 14 weeks, decreased to € 2,333, € 2,750 and € 798 per patient per year in FM, CLBP and AS respectively. Both sensitivity analyses did not influence the conclusions on the differences in costs.
Discussion
Patients with FM and CLBP referred to a specialist express a lower general well-being and are economically more costly than patients with AS. Although the poor experienced general well being in patients with unexplained pain has been recognised [5] , this is the first study to show these patients behave economically different. Especially the direct non-medical and the productivity costs were remarkably higher in FM and CLBP. This points to the important impact of both pain syndromes on functioning, in private as well as in professional life. Also, within the medical costs some remarkable differences between FM and CLBP on the one hand and AS on the other hand were noted. Costs for disease related hospitalisations, alternative medicine and over the counter drugs tended to be higher in FM and CLBP, but costs for physiotherapy and prescription drugs were higher in patients with AS. Explaining such differences is complex, since medical resource utilisation does not simply reflects the behaviour of the patient but is influenced also by the physician's behaviour, who has his scientific conviction but works at the same time within the constraints of the healthcare system. The higher costs for physiotherapy and prescription drugs in patients AS for example, might illustrate that healthcare providers recognise that physiotherapy and drugs fail to have sustained effects in FM and CLBP while they are considered standard treatment for AS. On the other hand, the maximised number of physiotherapy sessions reimbursed by the Dutch healthcare payer for non-inflammatory musculoskeletal disorders is likely an additional explanation. Remarkably, costs for alternative medicine and non-prescription drugs were higher in FM and CLBP, likely reflecting the quest of these patients to find for their complaints. In multivariate analyses the influence of the diagnostic group was the only variable to explain differences in total costs and general well being.. Although this study was not designed to compare costs and well being but was a secondary analysis of three distinct studies, the main strength was that disease related resource utilisation was assessed in each study by the same cost-diary and the same cost-estimates (2002). However, we recognise the analysis has several limitations. First, there was a difference in inclusion criteria. Patients with FM and CLBP were referred by general practitioners and/or medical specialists while patients with AS were recruited from the patients society and might represent a sample with less severe disease and therefore different health resource utilisation. However, labour force participation (56% versus 55%), general well being (67 versus 68) and the average total costs (€ 3,205 versus € 3,470) per AS patient were comparable with the average costs reported in a Dutch group of patients who were under care of a rheumatologist (22, 24). On the other hand, patients with FM and CLBP were referred to a specialist and are likely to represent a more severe spectrum of the disease and the health resource utilisation and costs of these patients is not generalisable to a population sample of patients with these diagnoses. In the Netherlands it is estimated that about 20 to 30% patients with chronic widespread pain and CLBP receive specialised care [2] . In this population sample of patients with CLBP, labour force participation was 57% which is much better than observed in our study. Other data to compare disease severity among population samples and hospital samples in FM or CLBP could not be found.
Therefore, data of this study are only generalisable to patients under control of a specialist.
Second, patients included in this analysis took part in a randomised controlled trial. It cannot be excluded that the longer duration of the intervention for patients with FM and CLBP contributed toward selection of patients having no paid work in these diagnostic groups.
Also, the intervention might have changed healthcare utilisation in the intervention groups.
Although in the AS and FM study a small reduction in resource utilisation was observed, extensive statistical testing could reliably exclude an influence of the intervention to explain the differences between the conditions. Third, there was a period of six years between the studies in FM and CLBP on the one hand and the study in AS on the other hand. By applying consumer price indices to the cost-estimates, we could correct for differential timing and evolution of prices. However, during the six years' period between the studies no major changes in financing of healthcare or social security were introduced in The Netherlands.
Finally, the initial cost-diary, which was used in the FM and CLBP study, did not consider the technical procedures, which could therefore not be taken into account. However, the costs of technical procedures are never a major cost-driver in musculoskeletal cost-of-illness studies and therefore it is unlikely the exclusion of these costs would have altered the present conclusions.
In the literature the high costs for FM and CLBP are confirmed. A top-down US study estimated the direct and productivity costs paid by a health insurance company for FM in 1998 at US$ 5,945 (€ 7,179 after adjusting for differential timing and differences in purchasing power parities between the Netherlands and USA) and were reported to be 2.4 times higher than in controls [7] . A longitudinal study among FM patients in the USA who are under care of a rheumatologist reported average annual direct healthcare costs in 1996 of US$ 2,274 (€2,847), which is higher than the direct healthcare costs in our patients.
However, costs of technical procedures were included and accounted for 7% of the total direct healthcare costs [8] . In a Canadian population based study in 1994, FM incurred 2.2-fold higher costs compared with non-pain controls for expenditures from the health insurance on physician visits, laboratory and radiology [6] . For CLBP, the total direct and productivity costs from the payer's perspective in a community sample were estimated at US$ 6,807 in1990 (€10,148) [22, 24] , being again higher than in our sample of patients under specialist care [9] . As mentioned, the annual costs found for AS were comparable with another Dutch study but were also comparable with a study among AS patients in the USA, reporting direct medical costs of US$1,775 (€ 2,091) [10] [11] [12] .
In addition to the costs per patient, the total national yearly cost per disease provides complementary information on the societal costs of the disease. In The Netherlands, prevalences of 5.3% (±0.7%) for chronic (> 3 months) widespread pain and of 21.2% (±1.7%) for CLBP [2] and of 0.1% for AS are accepted [3] . It is accepted that 20 to 30% of patients with FM were under care of a medical specialist and 30 to 40% of patients with CLBP were under care of general practitioner or medical specialist [2] . Considering 11,8 million Dutch inhabitants, the above considerations would result in 125,372 patients with FM, 752,226 patients with CLBP and 11,827 patients with AS reflecting the profile of the patients studied in our analyses. This would result in average annual costs of € 980 million, € 6,418 million and € 38 million for FM, CLBP and AS respectively for the Netherlands.
Conclusion:
While for the patients and specialists physicians the impact of the unexplained pain syndromes on general well being is a major problem, for society the economic consequences are high, at least when compared with patient being diagnosed with AS, an specific inflammatory disease. Table 4 . Determinants of the direct medical, direct non-medical, productivity and total costs assessed by Cox proportional hazard analysis with costs as outcome. 
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